Top

Published in:

01-05-2022 | Shingles | Clinical study

Serious adverse events with tofacitinib versus TNF inhibitors

Published in: Reactions Weekly | Issue 1/2022

Excerpt

Tofacitinib use does not increase the risk of serious adverse events (SAEs) compared with tumour necrosis factor inhibitor (TNFi) use in Korean patients with ulcerative colitis (UC), according to findings of a study published in the Journal of Korean Medical Science. …

Seo GH, et al. The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database Journal of Korean Medical Science 37: e123, No. 16, 25 Apr 2022. Available from: URL: http://doi.org/10.3346/jkms.2022.37.e123

Title: Serious adverse events with tofacitinib versus TNF inhibitors
Publication date: 01-05-2022
Publisher: Springer International Publishing
Keywords: Shingles
Ulcerative Colitis
TNF-Inhibitors
Phlebothrombosis
Unstable Angina
Golimumab
Published in: Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-022-14402-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Serious adverse events with tofacitinib versus TNF inhibitors

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Amoxicillin/clavulanic-acid/clindamycin/vancomycin

Multiple drugs

Methylprednisolone/tocilizumab

Apixaban/warfarin

Pembrolizumab

Paliperidone/quetiapine/carbamazepine